Converging Cancer Seminar Series – Engineering and Physical Sciences to Advance Cancer Research (Chemistry and Bioengineering) | Events
In this webinar series presented by the Cancer Research UK Convergence Science Center at Imperial College London and the Institute of Cancer Research in London, researchers from both organizations will discuss the main challenges facing cancer research and the opportunities for new converging scientific approaches to address these. Join us to examine how new approaches and technologies could shed light on unresolved issues in cancer biology, innovate new ways to tackle cancer challenges, and bring pioneering treatments to cancer patients faster.
Hosted by the Scientific Director of the Center for Convergence Sciences, Professor Axel Behrens, the series aims to support the Centre’s mission to facilitate collaboration between traditionally separate and distinct disciplines.
Please join us on Thursday November 4, 3:00 p.m. to 4:00 p.m., for two conferences of:
Dr Nazila Kamaly – Department of Chemistry, Imperial College London
“Nanomedicines and their role in modern cancer therapy”
The administration and therapy of drugs activated by nanoparticles is revolutionizing the field of medicine, as we have seen recently with vaccines based on solid lipid nanoparticles based on Covid-19 mRNA. For the past two decades, the application of nanotechnology in oncology has aimed to provide more effective and safer cancer treatment, with commonly used nanotherapies such as Doxil now on the market as ‘nanosimilars’. Considerable technological success has been achieved in this area although we have not seen a new paradigm shift in cancer therapy with nanodrugs. This is in part due to challenges arising from the complexities and heterogeneity of tumor biology, an incomplete understanding of nano-bio interactions and complex chemistries, scaling, fabrication and required controls. for clinical translation and commercialization, which the field is actively addressing and will be discussed in this conference.
Dr Nazila Kamaly is a lecturer in the Department of Chemistry and an expert in nanomedicine. She uses bioinspired approaches to develop targeted multifunctional polymeric nanomedicines capable of modifying their surface or core properties in response to local or upregulated disease markers for precise, stimuli-responsive and spatiotemporally controlled drug delivery. His laboratory is also developing biomimetic and biomicrofluidic models to better screen and understand nano-bio interactions at the cellular level.
Dr Nuria Oliva-Jorge – Department of Bioengineering, Imperial College London
“Selective tumor nanotherapies against cancer”
In this talk, Dr. Oliva-Jorge will describe the new approaches developed in her group to achieve tumor selectivity of cancer treatments using nanotechnology. It is not uncommon for powerful anti-cancer drugs to have dose-limiting toxicity, due to their unintended effects on healthy cells. Using rational nanoparticle design and engineering, we can enable the selective uptake of nanoparticles and / or drug release in cancer cells only, thereby minimizing side effects on healthy cells.
Dr Nuria Oliva-Jorge is currently a research fellow at Imperial College in the Department of Bioengineering. An organic chemist by training, Nuria obtained her doctorate in medical engineering and medical physics from MIT in 2016. Her thesis focused on biomaterials combined with nanotechnology for the local treatment of breast cancer. In 2018, Nuria joined the Almquist laboratory at Imperial College London as a postdoctoral fellow to work on nanotechnologies for wound healing and tissue regeneration. His independent group works at the intersection of biomaterials, biology and medicine to develop new smart medical technologies to fight complex human diseases.
To receive information on how to access this event, please send an email [email protected]
Note: This webinar is exclusively for colleagues at the Institute of Cancer Research, Imperial College London, Royal Marsden Hospital and Imperial College Healthcare.